Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial

Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial

Enrique Martínez,1 Maite Martínez,1 Mikel Rico,1 Berta Hernández,1 Francesc Casas,2 Nuria Viñolas,2 Ana Pérez-Casas,3 Manuel Dómine,3 Julián Mínguez4 1Radiation Oncology Services, Hospital of Navarra, Pamplona,...

Full description

Bibliographic Details
Main Authors: Martínez E, Martínez M, Rico M, Hernández B, Casas F, Viñolas N, Pérez-Casas A, Dómine M, Mínguez J
Format: Article
Language:English
Published: Dove Medical Press 2016-03-01
Series:OncoTargets and Therapy
Subjects:
non-small-cell lung cancer
radiotherapy
chemotherapy
erlotinib
concurrent.
Online Access:https://www.dovepress.com/feasibility-tolerability-and-efficacy-of-the-concurrent-addition-of-er-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/feasibility-tolerability-and-efficacy-of-the-concurrent-addition-of-er-peer-reviewed-article-OTT

Similar Items